Twelve months exenatide treament in type 2 diabetes and severe obesity

M Dieguez Felechosa; C Tuson Rovira; C Sanchez Ragnarsson; E Suarez-LLedo Alemany; L Cacho Garcia; N Valdes Gallego; J Prieto Santiago

P679

Prev Next

Section Contents Cite

Endocrine Abstracts (2011) 26 P679

ECE2011 Poster Presentations Diabetes therapy (26 abstracts)

Twelve months exenatide treament in type 2 diabetes and severe obesity

M Diéguez Felechosa ¹ , C Tusón Rovira ¹ , C Sánchez Ragnarsson ² , E Suárez-LLedo Alemany ¹ , L Cacho Garcia ² , N Valdes Gallego ¹ & J Prieto Santiago ¹

Err

Author affiliations

¹Hospital de Cabueñes, Gijón, Spain; ²Hospital Universitario Central de Asturias, Oviedo, Spain.

Aim: To assess the effectiveness, safety and tolerability of Exenatide twice daily treatment of type 2 diabetes and obesity.

Material and methods: Data analysis of obese type 2 diabetic patients initiated on Exenatide therapy in our Endocrine clinics who complete 1 year of treatment.

Results: We included 42 patients, 30 women (71.4%) and 12 men (28.6%), mean (±S.D.) age 57±10 and 9±7 years diabetes evolution. At baseline, mean HbA1c was 7.45±1.4%. and mean weight 105.8±16 kg with body mass index (BMI) 41.1±5.7 kg/m², 57% of them being morbidly obese patients. 95.2% included Metformin in their basal treatment, alone or in combination with others oral antidiabetic drugs. Seven patients were receiving insulin therapy, stopped at the moment of Exenatide initiation. We did not include any modifications in previous lifestyle plans. After 12 months of treatment mean HbA1c reduction was 0.8±1.8% with 69% of patients reaching HbA1c<7%. Mean weight loss was 7.6±8, 4.5±5, 5.9±7 and 7.6±8 kg at 3, 6 and 12 months respectively with a BMI reduction of 2.83±2.9 kg/m². All of these differences were statistically significant (P<0.01 Wilcoxon test). We did not find any significant change in blood pressure, lipid profile or renal function. Adverse effects occurred in 31% of patients, mainly mild to moderate gastrointestinal ones that conditioning Exenatide withdrawal in one patient. Hypoglycaemia was reported in three patients, being all of them on concomitant sulfonylurea treatment.

Conclusions: In our experience, Exenatide provides glycemic control and a substantial weight loss that occurs early in treatment being an excellent option in diabetic patients from whom weight gain is a main concern.